Quick Answer
Metagenomi Therapeutics, Inc. reported Cash and Equivalents of $41.72 million for fiscal year 2025.
Metagenomi Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $41.72M | +52.3% |
| 2024 | $27.39M | -80.5% |
| 2023 | $140.60M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.77M | +30.5% | +22.1% |
| June 30, 2025 | $26.85M | -56.1% | -8.0% |
| March 31, 2025 | $29.20M | -71.5% | +6.6% |
| December 31, 2024 | $27.39M | -80.5% | +9.0% |
| September 30, 2024 | $25.12M | -75.4% | -58.9% |
| June 30, 2024 | $61.18M | +18.5% | -40.3% |
| March 31, 2024 | $102.56M | +7.2% | -27.1% |
| December 31, 2023 | $140.60M | — | +38.0% |
- Metagenomi Therapeutics, Inc. showed an increase of +52.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Metagenomi Therapeutics, Inc.’s cash and equivalents has declined by 70.3% (from $140.60 million to $41.72 million).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: